Transgenic mouse expressing human FcRn protein
Disclosed is a transgenic knockout mouse whose genome comprises a homozygous disruption in its endogenous FcRn gene. The homozygous RcRn disruption prevents the expression of a functional FcRn protein, resulting in a transgenic knockout mouse in which exogenously administered IgG1 exhibits a substantially shorter half-life, as compared to the half-life of exogenously administered IgG1 in a wild-type mouse. The transgenic knockout mouse with a homozygous RcRn disruption is also unable to absorb maternal IgG in the prenatal or neonatal stage of development. Also disclosed is a transgenic knockout mouse comprising a homozygous FcRn disruption and a human FcRn transgene. The transgenic addition of human FcRn results in a substantial increase in the half-life of exogenously administered human IgG1. Methods of using the transgenic knockout mouse, and cells derived from them, are also disclosed.
1. A transgenic mouse whose genome comprises a homozygous disruption in its endogenous FcRn gene and further comprises a DNA sequence encoding a human FcRn (huFcRn) operably linked to a regulatory sequence, wherein said homozygous disruption prevents the expression of a functional murine FcRn protein, and wherein the mouse expresses a functional huFcRn protein.
2. The transgenic mouse of claim 1 , wherein the functional huFcRn protein is expressed from a huFcRn cDNA construct.
3. The transgenic mouse of claim 1 , wherein the functional huFcRn protein is expressed from a complete huFcRn gene.
4. The transgenic mouse of claim 1 , wherein the huFcRn transgene is operably linked to an endogenous FcRn regulatory sequence.
5. The transgenic mouse of claim 1 , wherein the huFcRn transgene is operably linked to an exogenous FcRn regulatory sequence.